Selected research
Industry Research
Age Related Macular Degeneration Drugs Industry Research Report 2026
Market perspective
The global Age Related Macular Degeneration Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Age Related Macular Degeneration Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Age Related Macular Degeneration Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Age Related Macular Degeneration Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Age Related Macular Degeneration Drugs include Novartis, Roche, Bayer Healthcare, Regeneron Pharmaceuticals, Neurotech Pharmaceuticals and Allergan, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Age Related Macular Degeneration Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (W Tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Age Related Macular Degeneration Drugs Market by Company
Novartis
Roche
Bayer Healthcare
Regeneron Pharmaceuticals
Neurotech Pharmaceuticals
Allergan
Age Related Macular Degeneration Drugs Segment by Type
Eylea
Avastin
Squalamine
Conercept
Lampalizamab
Lucentis
Others
Age Related Macular Degeneration Drugs Segment by Application
50-60 Years Old
60-70 Years Old
Others
Age Related Macular Degeneration Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Age Related Macular Degeneration Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Age Related Macular Degeneration Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Age Related Macular Degeneration Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Age Related Macular Degeneration Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Age Related Macular Degeneration Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Age Related Macular Degeneration Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Eylea
- Avastin
- Squalamine
- Conercept
- Lampalizamab
- Lucentis
- Others
Applications
- 50-60 Years Old
- 60-70 Years Old
- Others
Companies covered
- Novartis
- Roche
- Bayer Healthcare
- Regeneron Pharmaceuticals
- Neurotech Pharmaceuticals
- Allergan
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Age Related Macular Degeneration Drugs Market Size (2021-2032)
- 2.2.2 Global Age Related Macular Degeneration Drugs Sales (2021-2032)
- 2.2.3 Global Age Related Macular Degeneration Drugs Market Average Price (2021-2032)
- 2.3 Age Related Macular Degeneration Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Eylea
- 2.3.3 Avastin
- 2.3.4 Squalamine
- 2.3.5 Conercept
- 2.3.6 Lampalizamab
- 2.3.7 Lucentis
- 2.3.8 Others
- 2.4 Age Related Macular Degeneration Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 50-60 Years Old
- 2.4.3 60-70 Years Old
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Age Related Macular Degeneration Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Age Related Macular Degeneration Drugs Sales (W Tons) of Manufacturers (2021-2026)
- 3.3 Global Age Related Macular Degeneration Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Age Related Macular Degeneration Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Age Related Macular Degeneration Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Age Related Macular Degeneration Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Age Related Macular Degeneration Drugs, Product Type & Application
- 3.8 Global Manufacturers of Age Related Macular Degeneration Drugs, Established Date
- 3.9 Global Age Related Macular Degeneration Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Novartis
- 4.1.1 Novartis Company Information
- 4.1.2 Novartis Business Overview
- 4.1.3 Novartis Age Related Macular Degeneration Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Novartis Age Related Macular Degeneration Drugs Product Portfolio
- 4.1.5 Novartis Recent Developments
- 4.2 Roche
- 4.2.1 Roche Company Information
- 4.2.2 Roche Business Overview
- 4.2.3 Roche Age Related Macular Degeneration Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Roche Age Related Macular Degeneration Drugs Product Portfolio
- 4.2.5 Roche Recent Developments
- 4.3 Bayer Healthcare
- 4.3.1 Bayer Healthcare Company Information
- 4.3.2 Bayer Healthcare Business Overview
- 4.3.3 Bayer Healthcare Age Related Macular Degeneration Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Bayer Healthcare Age Related Macular Degeneration Drugs Product Portfolio
- 4.3.5 Bayer Healthcare Recent Developments
- 4.4 Regeneron Pharmaceuticals
- 4.4.1 Regeneron Pharmaceuticals Company Information
- 4.4.2 Regeneron Pharmaceuticals Business Overview
- 4.4.3 Regeneron Pharmaceuticals Age Related Macular Degeneration Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Regeneron Pharmaceuticals Age Related Macular Degeneration Drugs Product Portfolio
- 4.4.5 Regeneron Pharmaceuticals Recent Developments
- 4.5 Neurotech Pharmaceuticals
- 4.5.1 Neurotech Pharmaceuticals Company Information
- 4.5.2 Neurotech Pharmaceuticals Business Overview
- 4.5.3 Neurotech Pharmaceuticals Age Related Macular Degeneration Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Neurotech Pharmaceuticals Age Related Macular Degeneration Drugs Product Portfolio
- 4.5.5 Neurotech Pharmaceuticals Recent Developments
- 4.6 Allergan
- 4.6.1 Allergan Company Information
- 4.6.2 Allergan Business Overview
- 4.6.3 Allergan Age Related Macular Degeneration Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Allergan Age Related Macular Degeneration Drugs Product Portfolio
- 4.6.5 Allergan Recent Developments
5 Global Age Related Macular Degeneration Drugs Market Scenario by Region
- 5.1 Global Age Related Macular Degeneration Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Age Related Macular Degeneration Drugs Sales by Region: 2021-2032
- 5.2.1 Global Age Related Macular Degeneration Drugs Sales by Region: 2021-2026
- 5.2.2 Global Age Related Macular Degeneration Drugs Sales by Region: 2027-2032
- 5.3 Global Age Related Macular Degeneration Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Age Related Macular Degeneration Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Age Related Macular Degeneration Drugs Revenue by Region: 2027-2032
- 5.4 North America Age Related Macular Degeneration Drugs Market Facts & Figures by Country
- 5.4.1 North America Age Related Macular Degeneration Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Age Related Macular Degeneration Drugs Sales by Country (2021-2032)
- 5.4.3 North America Age Related Macular Degeneration Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Age Related Macular Degeneration Drugs Market Facts & Figures by Country
- 5.5.1 Europe Age Related Macular Degeneration Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Age Related Macular Degeneration Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Age Related Macular Degeneration Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Age Related Macular Degeneration Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Age Related Macular Degeneration Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Age Related Macular Degeneration Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Age Related Macular Degeneration Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Age Related Macular Degeneration Drugs Market Facts & Figures by Country
- 5.7.1 South America Age Related Macular Degeneration Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Age Related Macular Degeneration Drugs Sales by Country (2021-2032)
- 5.7.3 South America Age Related Macular Degeneration Drugs Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Age Related Macular Degeneration Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Age Related Macular Degeneration Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Age Related Macular Degeneration Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Age Related Macular Degeneration Drugs Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Age Related Macular Degeneration Drugs Sales by Type (2021-2032)
- 6.1.1 Global Age Related Macular Degeneration Drugs Sales by Type (2021-2032) & (W Tons)
- 6.1.2 Global Age Related Macular Degeneration Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Age Related Macular Degeneration Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Age Related Macular Degeneration Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Age Related Macular Degeneration Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Age Related Macular Degeneration Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Age Related Macular Degeneration Drugs Sales by Application (2021-2032)
- 7.1.1 Global Age Related Macular Degeneration Drugs Sales by Application (2021-2032) & (W Tons)
- 7.1.2 Global Age Related Macular Degeneration Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Age Related Macular Degeneration Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Age Related Macular Degeneration Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Age Related Macular Degeneration Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Age Related Macular Degeneration Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Age Related Macular Degeneration Drugs Value Chain Analysis
- 8.1.1 Age Related Macular Degeneration Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Age Related Macular Degeneration Drugs Production Mode & Process
- 8.2 Age Related Macular Degeneration Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Age Related Macular Degeneration Drugs Distributors
- 8.2.3 Age Related Macular Degeneration Drugs Customers
9 Global Age Related Macular Degeneration Drugs Analyzing Market Dynamics
- 9.1 Age Related Macular Degeneration Drugs Industry Trends
- 9.2 Age Related Macular Degeneration Drugs Industry Drivers
- 9.3 Age Related Macular Degeneration Drugs Industry Opportunities and Challenges
- 9.4 Age Related Macular Degeneration Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst